Cover Image

Nanomedicine in cancer immunotherapy /

Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel,...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Kesharwani, Prashant (Editor)
Format: eBook
Language:English
Published: London, United Kingdom : Academic Press, 2024.
Subjects:
Cancer > Immunotherapy.
Nanomedicine.
Drug delivery systems.
Immunotherapy.
Nanomedicine
Drug Delivery Systems
Immunotherapy
Cancer > Immunothérapie.
Nanomédecine.
Systèmes d'administration de médicaments.
Immunothérapie.
Electronic books.
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Front Cover
  • Nanomedicine in Cancer Immunotherapy
  • Copyright Page
  • Dedication
  • Contents
  • List of contributors
  • About the editor
  • Preface
  • Acknowledgments
  • 1 Immunoadjuvants for cancer immunotherapy
  • 1.1 Why adjuvants for cancer immunotherapy?
  • 1.2 Nanostructures for cancer immunotherapy
  • 1.3 Viruses against cancer
  • 1.4 Combined approaches for immunotherapy against cancer
  • 1.5 Emerging cationic nanoadjuvants for cancer immunotherapy
  • Acknowledgments
  • References
  • 2 Nanotechnology as an emerging option in cancer immunotherapy
  • 2.1 Introduction
  • 2.2 Traditional methods used in cancer treatment
  • 2.2.1 Surgery
  • 2.2.2 Chemotherapy
  • 2.2.3 Radiotherapy
  • 2.3 Cancer immunotherapy
  • 2.3.1 Disadvantages of cancer immunotherapies
  • 2.3.1.1 Variability in the immune response
  • 2.3.1.2 Growing resistance to immunotherapies
  • 2.3.1.3 Problems derived from the immune system
  • 2.4 Different adoptive cellular transfer immunotherapies strategies for cancer
  • 2.4.1 Tumor infiltrating lymphocytes
  • 2.4.2 Cytokine-induced killer cells
  • 2.4.3 T-cell receptor
  • 2.4.4 Chimeric antigen receptor T cells
  • 2.5 Nanotechnology-associated cancer immunotherapy strategies
  • 2.6 Types of nanoparticles used in cancer immunotherapy
  • 2.6.1 Polymeric nanoparticles
  • 2.6.2 Lipid-based nanoparticles
  • 2.6.3 Inorganic nanoparticles
  • 2.6.4 Some examples of the types above of nanoparticles
  • 2.6.4.1 Liposomes
  • 2.6.4.2 Gold nanoparticles
  • 2.6.4.3 PLGA nanoparticles
  • 2.7 The targeted delivery of nanoparticles with cancer immunotherapy
  • 2.7.1 Targeting immunological cells with nanoparticles
  • 2.7.2 Antigen intracellular delivery
  • 2.8 Direct immune checkpoint inhibition with nanoparticles
  • 2.8.1 PD-L1
  • 2.8.2 CTLA-4
  • 2.8.3 Resistance to immune checkpoint blockage.
  • 2.8.4 Effect of physicochemical properties on vaccine nanocarriers design
  • 2.8.5 Nanoparticles as a carrier of mRNA cancer vaccine
  • 2.9 Conclusion
  • References
  • Further reading
  • 3 Different administration routes for nanovectors in cancer immunotherapy
  • 3.1 Introduction
  • 3.2 Types of nanovectors used in cancer immunotherapy
  • 3.3 Deficiencies in delivery and efficacy of nanovectors
  • 3.4 Nanovectors targeting mechanisms
  • 3.4.1 Passive targeting
  • 3.4.2 Active targeting
  • 3.5 Nanovectors' administration routes
  • 3.6 Transdermal delivery
  • 3.6.1 Molecular size
  • 3.6.2 Affinities
  • 3.6.3 Solubility
  • 3.6.4 Ionization
  • 3.7 Subcutaneous delivery
  • 3.8 IV delivery
  • 3.9 Oral delivery
  • 3.10 Inhalation (pulmonary) delivery
  • 3.11 Intramuscular delivery
  • 3.12 Intraperitoneal delivery
  • 3.13 Intranasal delivery
  • 3.14 Rectal delivery
  • 3.15 Vaginal delivery
  • 3.16 IT delivery
  • 3.17 Conclusion and future prospects
  • References
  • 4 Two-dimensional material-based nanomedicines for cancer immunotherapy
  • 4.1 Introduction
  • 4.2 Main 2D materials and their applications in cancer immunotherapy
  • 4.2.1 Graphene and its derivatives
  • 4.2.1.1 Properties and preparation methods of graphene and its analogs
  • 4.2.1.2 The applications of graphene and its analogs in cancer immunotherapy
  • 4.2.2 Black phosphorus
  • 4.2.2.1 Properties and preparation methods of black phosphorus
  • 4.2.2.2 The applications of black phosphorus in cancer immunotherapy
  • 4.2.3 Transition metal chalcogenides
  • 4.2.3.1 Properties and preparation methods of transition metal chalcogenides
  • 4.2.3.2 The applications of transition metal chalcogenides in cancer immunotherapy
  • 4.2.4 2D carbides and nitrides (MXenes)
  • 4.2.4.1 Properties and preparation methods of MXenes
  • 4.2.4.2 The applications of MXenes in cancer immunotherapy.
  • 4.2.5 Other 2D materials
  • 4.3 Summary and perspectives
  • Acknowledgments
  • Conflicts of interest
  • References
  • 5 Hydrogel-based nanomedicines for cancer immunotherapy
  • 5.1 Introduction
  • 5.1.1 Cancer
  • 5.1.2 Cancer immunotherapy
  • 5.2 Nanotechnology and nanomedicine
  • 5.2.1 Diagnostics
  • 5.2.2 Regenerative medicine
  • 5.2.3 Drug delivery
  • 5.3 Role of nanotechnology in cancer immunotherapy
  • 5.4 Nanomaterials
  • 5.5 Hydrogels
  • 5.5.1 Classification of hydrogels
  • 5.5.1.1 Natural, synthetic, or semi-synthetic (hybrid) hydrogels
  • 5.5.1.2 Homopolymers, copolymers, interpenetrating networks (IPNs), and semi-IPNs hydrogels
  • 5.5.1.3 Chemical and physical hydrogels
  • 5.5.1.4 Nonionic, anionic, cationic, and ampholytic hydrogels
  • 5.5.1.5 Macroscopic gels, microgels, and nanogels
  • 5.5.1.6 Amorphous, crystalline, and semi-crystalline hydrogels
  • 5.5.1.7 Smart hydrogels
  • 5.6 Hydrogel-based approaches in cancer immunotherapy
  • 5.6.1 Delivery
  • 5.6.1.1 Delivery of small molecules
  • 5.6.1.2 Delivery of macromolecular drugs
  • 5.6.1.3 Codelivery of immunotherapeutic agents
  • 5.6.1.4 Immune cell delivery
  • 5.6.2 Vaccines
  • 5.6.3 Chemotherapy-combinational immunotherapy
  • 5.6.4 Cellular immunotherapy
  • 5.6.5 Inflammation modulation
  • 5.6.6 Phototherapy-combinational immunotherapy
  • 5.7 Conclusion and future perspective
  • References
  • 6 Exosomes-based nanomedicines for cancer immunotherapy
  • 6.1 Introduction
  • 6.1.1 Cancer and nanotechnology
  • 6.1.2 Current challenges to cancer nanomedicines and possible adaptations
  • 6.2 Exosomes for cancer immunotherapy
  • 6.2.1 Exosomes for treatment of lung cancer (LC)
  • 6.2.2 Exosomes for treatment of cervical cancer
  • 6.2.3 Exosomes for treatment of breast cancer
  • 6.3 Summary
  • Acknowledgment
  • Conflict of interest
  • References.
  • 7 Lipid-based nanomedicines for cancer immunotherapy
  • 7.1 Introduction
  • 7.2 Cancer immunotherapy
  • 7.3 Immunotherapeutic delivery systems
  • 7.4 Different kinds of nanocarriers that are based on lipids
  • 7.4.1 Solid lipid nanoparticles (SLNs)
  • 7.4.2 Nanostructured lipid carriers (NLC)
  • 7.4.3 Liposome
  • 7.4.4 Niosomes
  • 7.5 Oral lipid nanomedicines
  • 7.6 Conclusions
  • References
  • 8 Inorganic nanoparticle-based nanomedicines for cancer immunotherapy
  • 8.1 Introduction of cancer immunotherapy
  • 8.2 Advantages of inorganic nanomaterials
  • 8.3 Silica nanomaterials for immunotherapy
  • 8.4 Gold-nanomaterials for immunotherapy
  • 8.5 Copper-nanomaterials for immunotherapy
  • 8.6 Magnetic nanomaterials for immunotherapy
  • 8.7 Carbon-nanomaterials for immunotherapy
  • 8.8 Quantum dots for immunotherapy
  • 8.9 Conclusion and perspective
  • Acknowledgments
  • Conflict of interests
  • References
  • Further reading
  • 9 Liposome-based nanomedicines for cancer immunotherapy
  • 9.1 Introduction
  • 9.2 Cancer immunotherapy
  • 9.2.1 Tumor-specific cellular immunotherapy
  • 9.2.2 Adoptive cellular immunotherapy
  • 9.2.3 NK-cell therapy
  • 9.2.4 CAR-T cell immunotherapy
  • 9.3 Nanomedicine in cancer immunotherapy
  • 9.4 Liposomes: an overview
  • 9.4.1 Conventional liposomes
  • 9.4.2 Cholesterol-conjugated liposomes
  • 9.4.3 pH-sensitive liposomes
  • 9.4.4 PEGylated or stealth liposomes
  • 9.4.5 Ligand-targeted liposomes
  • 9.4.6 Immunoliposomes
  • 9.4.7 Multifunctional liposomes
  • 9.5 Liposomes in cancer immunotherapy
  • 9.5.1 Liposome-based active targeting in cancer immunotherapy
  • 9.5.2 Liposome-based passive targeting in cancer immunotherapy
  • 9.6 Challenges and future prospects
  • 9.7 Conclusion
  • Acknowledgement
  • Conflict of interest
  • References
  • 10 Biomembrane-based nanoparticles for cancer immunotherapy.
  • 10.1 Red blood cell membrane-based nanoparticles
  • 10.2 White blood cell membrane-based nanoparticles
  • 10.3 Platelet membrane-based nanoparticles
  • 10.4 Mesenchymal stem cell membrane-based nanoparticles
  • 10.5 Cancer cell membrane-based nanoparticles
  • 10.6 Bacterial membrane-based nanoparticles
  • 10.7 Hybrid biomembrane-based nanoparticles
  • 10.8 Conclusion and outlook
  • References
  • 11 Dendrimer-based nanomedicines for cancer immunotherapy
  • 11.1 Introduction
  • 11.2 Synthesis and characterization of dendrimer nanoparticles
  • 11.3 Dendrimers as general carriers for drug delivery
  • 11.4 Dendrimer and enhancement of cancer immune responses
  • 11.5 Dendrimers as vehicles for cancer immunotherapy
  • 11.5.1 Cytokine-based immunotherapy
  • 11.5.2 Vaccines
  • 11.5.3 Monoclonal antibody-based therapy
  • 11.5.4 Immune checkpoint inhibitors (ICIs)-based therapy
  • 11.6 Dendrimer-based drug carriers in different cancers
  • 11.7 Conclusions and future perspectives
  • References
  • 12 Magnetic nanocarriers for cancer immunotherapy
  • 12.1 Cancer immunotherapy
  • 12.2 Magnetic nanocarriers
  • 12.3 Magnetic nanocarrier for cancer immunotherapy
  • 12.3.1 Physicochemical properties of magnetic nanocarrier and cancer immunotherapy
  • 12.3.1.1 Effects of magnetic nanocarrier size on cancer immunotherapy
  • 12.3.1.2 Effects of magnetic nanocarrier shape on cancer immunotherapy
  • 12.3.1.3 Effects of magnetic nanocarrier surface charge on cancer immunotherapy
  • 12.3.2 Surface functionalization of magnetic nanocarrier for cancer immunotherapy
  • 12.3.2.1 Cell membrane-coated magnetic nanocarrier for cancer immunotherapy
  • 12.4 Definition of hyperthermia
  • 12.4.1 Magnetic hyperthermia
  • 12.4.2 Magnetic hyperthermia and cancer immunotherapy
  • 12.5 Magnetic vaccination
  • 12.6 Magnetic nanoparticle nanotheranostics
  • 12.7 Conclusion
  • References.